GNFT

Genfit S.A. (NASDAQ:GNFT) is a French biopharmaceutical company founded in 1999 and headquartered in Loos, France. The company went public on NASDAQ in March 2019, focusing on the discovery and development of drug candidates and diagnostic solutions for metabolic and liver-related diseases. Genfit operates in the specialized field of hepatology, developing treatments for conditions such as primary biliary cholangitis, nonalcoholic steatohepatitis (NASH), and cholangiocarcinoma, while also creating diagnostic tools to detect liver diseases.